EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, and Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, have announced the signing of Memorandum of Understanding (MoU), which will see the two organisations collaborating on establishing and strengthening CAR T-cell therapy development and manufacturing capabilities at EVA Pharma’s facilities.
Under the MOU, the partnership will prioritise the development and large-scale manufacturing of high-quality lentiviral vectors, a critical component in CAR T-cell therapies for leukemia and other blood cancers.
Porton Advanced will leverage its expertise in viral vector and CAR-T cell therapy process development and manufacturing to support EVA Pharma’s efforts to deliver safe, effective, and scalable treatments.
The collaboration brings together Porton Advanced' s cutting-edge expertise in viral vector and cell therapy manufacturing with EVA Pharma's growing footprint in high-tech biopharmaceuticals and its established regional infrastructure and market leadership across the Middle East and Africa (MEA). This will support technology transfer and local production capabilities for innovative cancer therapies while ensuring the highest quality standards.
The agreement aligns with global efforts to expand access to advanced immunotherapies, particularly in markets with limited cell and gene therapy infrastructure. By establishing localised production hubs in Egypt and Saudi Arabia, the partnership aims to reduce costs, shorten treatment timelines, and set new standards for oncology care in the MEA region.
